Medical publishers get involved in #worldheartday…
Learn more about the potential impact of cOAlition S: a commitment to make all European publicly funded research freely available by 2020.
In a recent publication, researchers examine whether funder open access platforms are a good idea.
Robert-Jan Smits, a senior European Commission official comments on whether open access for all scientific papers by 2020 is a realistic goal.
CBI’s Publication Planning Meeting is back by popular demand with new dates and an exciting new programme.
In a recent MAP newsletter, ISMPP share an update from ASCO on their new open access option for industry-funded research.
Building bridges: establishing a central scholarly platform for all-content discovery, access and use
How can publishers move towards the provision of seamless centralised access to all content?
Don’t forget! From 1 July 2018, ICMJE requires all reports of clinical trial data to include a data sharing statement.
Elizabeth Knowles, Associate Editorial Director at Taylor & Francis, explains the principles of open access.
Missed the 14th Annual Meeting of ISMPP? Read the second part of our meeting report to get up to speed!
A new study from the AllTrials team sheds light on clinical trial reporting rates by non-industry sponsors.
As discussions continue on how best to balance open science with copyright protection, ResearchGate and publishers collaborate on the issue.
A new, regular series in The BMJ will highlight a different unreported clinical trial every week, with the intention of improving reporting rates.
Can preprints be cited in the same way as papers published in a peer reviewed journal, or do we need to define new standards?
A study finds that the most common form of open access is ‘bronze’, meaning that data are free to read but not re-use. This is likely to have negative implications for research.
A recent review article examines the benefits of open access versus the economic realities of this publishing model.